<DOC>
	<DOC>NCT01770834</DOC>
	<brief_summary>This prospective, observational study will evaluate the efficacy, safety and tolerability of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have had an inadequate response or are intolerant to one or more conventional disease-modifying anti-rheumatic drugs. Data will be collected from patients initiated on RoActemra/Actemra treatment according to the local label at baseline, Weeks 4, 12 and 24, and at 3 and 6 months after the last dose of study drug.</brief_summary>
	<brief_title>A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/= 21 years of age Moderate to severe active rheumatoid arthritis (DAS28 &gt;/= 3.2) Inadequate response to one or more conventional diseasemodifying antirheumatic drugs (DMARDs) Initiated on RoActemra/Actemra treatment in accordance with the prescribing information Pregnant or lactating women Contraindication to RoActemra/Actemra treatment according to the local labelling Previous treatment with tocilizumab Treatment with any investigational agent within 4 weeks (or 5 halflives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra Women of childbearing potential not using effective methods of contraception as defined by protocol</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>